Accelus Adds Two New Members to its Board

Accelus has welcomed Kevin McGann and Bernie Haffey to its Board of Directors. 

“I am delighted by the addition of Kevin McGann and Bernie Haffey to the Accelus Board of Directors,” Board Chairman Alex Lukianov said. “Their leadership and depth of expertise will be instrumental to becoming the global market leader in expandable spinal implants as we strive to refine and advance procedures for superior patient outcomes.”
 
McGann joined Accelus in 2019 and has been its president and CEO since April 2023. His tenure with the company includes roles as president and chief commercial officer. McGann’s background in the spine industry includes various positions at some of the largest orthopedic implant manufacturers, including vice president of Sales at Stryker Spine, vice president of U.S. Sales for Medtronic Spine and Biologics, and area director of Sales for Kyphon. Additionally, he served as president of Lumenis Inc. and regional sales director for U.S. Surgical.

McGann earned a B.S. in business administration from Villanova University.
 
The founder of Haffey & Co., Haffey has more than 20 years of experience utilizing the High-Performance Management System (HPMS) framework to achieve prime customer, employee and financial results that has helped transform more than 50 organizations. Haffey’s career includes serving as president and CEO of two venture-backed startups—Nexis Vision Inc. and NDO Surgical Inc.—both of which achieved structured exits under his leadership. Additionally, he was executive vice president and chief commercial officer at both Summit Technology Inc., and IntraLase Corp. These startups achieved revenues that exceeded $100 million and exits of $1 billion and $800 million, respectively. He currently serves on the Board of Directors of On Target Laboratories Inc. and Medevise Consulting, and previously served on the boards of WaveTec Vision Inc., acquired by Alcon Labs, and Ocular Therapeutix Inc.

Haffey earned a BA from Colgate University and an MBA from Cornell University.
 
Under its leadership team, Accelus is centering its efforts on both global and U.S. expansion of its spinal technologies with a primary focus on its Adaptive Geometry technology, best exemplified by its flagship product, the FlareHawk Interbody Fusion System and its Toro-L biplanar-expandable lateral implant. With controlled, multidirectional expansion, these implants are designed to adapt to the specific anatomical requirements of each patient to improve surgical outcomes by restoring foraminal height, reestablishing sagittal balance, and reducing the risk of subsidence. Complementing its interbody portfolio, Accelus also offers the LineSider Spinal System, a versatile posterior screw system that gives surgeons the ability to tailor their surgical construct to each patient’s pathology, as well as BioNest allograft bone matrix, a human allograft demineralized bone matrix (DBM) designed for ease of flow for post-pack graft delivery into the surgical site.

Accelus develops expandable spinal implant technology whose Adaptive Geometry solutions are specifically designed for transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF), endoscopic-assisted, percutaneous, and lateral spine surgeries.